参考文献

［1］Cusack Mary，Kellar Ed，Barnes Shelly，et al.Transcelerate risk-based monitoring technology considerations part 2［R/OL］.（2015-12-15）［2019-12-22］.https：//www.transceleratebiopharmainc.com/wp-content/uploads/2013/10/TransCelerate-RBM-Position-Paper-FINAL-30MAY2013.

［2］FDA.Guidance for industry，oversight of clinical investigations—a risk-based approach to monitoring［R/OL］.（2013）［2019-10-28］.https：//www.fda.gov/regulatory-information/search-fda-guidancedocuments/oversight-clinical-investigations-risk-based-approach-monitoring.

［3］European Commission.Guidance for the preparation of good clinical practice inspection reports［R/OL］.（2011）［2011-11-10］.http：//ec.europa.eu/health/files/eudralex/vol-10/chap4/guidance＿for＿the＿preparation＿of＿good＿clinical＿practice＿inspection＿reports＿en.

［4］European Medicines Agency.Reflection paper on risk based quality management in clinical trials［R/OL］.（2011）［2019-12-22］.https：//www.ema.europa.eu/en/documents/scientific-guideline/reflection-paperrisk-based-quality-management-clinical-trials＿en-0.

［5］European Medicines Agency.Reflection paper on risk-based quality management in clinical trials［R/OL］.（2013）［2019-12-22］.https：//www.ema.europa.eu/en/documents/scientific-guideline/reflection-paperrisk-based-quality-management-clinical-trials＿en.

［6］EMA.Guideline for good clinical practiceE6（R2）［R/OL］.（2016）［2019-12-22］.https：//www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5＿en.

［7］FDA.E6（R2）Good clinical practice：integrated addendum to ICH E6（R1）guidance for industry［R/OL］.（2018）［2019-12-22］.https：//www.fda.gov/media/93884/download.

［8］Streicher-Saied U，Gertzen H，Hecht A，et al.Investigator site audit performance［J］.Appl Clin Trials，2006，15：95-99.